Navigation Links
Global Markets for Enzyme Inhibitors -- Focus on Emerging Markets
Date:8/28/2012

NEW YORK, Aug. 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Global Markets for Enzyme Inhibitors -- Focus on Emerging Markets

http://www.reportlinker.com/p0919322/Global-Markets-for-Enzyme-Inhibitors----Focus-on-Emerging-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

 

REPORT SCOPE

 

INTRODUCTION

 

STUDY GOALS AND OBJECTIVES

 

The overall goal of this study is to provide a comprehensive understanding of the current and future characteristics of the global market for enzyme inhibitors.

 

This report explores present and future strategies within the market for enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors. The improvements in the market and the setbacks and needs of the market are discussed in this report. The comparisons, usage, and advantages and disadvantages of different types of enzyme inhibitors are also discussed in this report.

 

A detailed analysis of the enzyme inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year forecast period of this report, from 2011 to 2016.

 

Applications for enzyme inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.

 

REASONS FOR DOING THE STUDY

 

Extensive research in the field of enzyme inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of enzyme inhibitors in their productions and processes. This has led to steady market growth for enzyme inhibitors.

 

Research and development (R&D) spending, along with increasing competition, patent expirations and new technologies, is directing this to a new level. Although, due to patent expirations, the overall revenue for the market has decreased slightly from 2009 to 2011, new advancements, new product launches and the changing lifestyle will cause the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

 

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.

 

CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE

 

This report provides invaluable information to manufacturers and users of PPIs, protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, PDE5 inhibitors, neuraminidase inhibitors, and ACE inhibitors. Pharmaceutical and biotechnology companies, research institutes, and physicians will find this study to be of interest.

 

SCOPE OF REPORT

 

The scope of this study encompasses enzyme inhibitors in the pharmaceutical and biotechnology industry. BCC Research analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. Emerging markets for enzyme inhibitors include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.

 

METHODOLOGY AND INFORMATION SOURCES

 

BCC conducted a comprehensive literature search, which included technical newsletters and journals. The data were collected through interviews and correspondence with technical experts manufacturing enzyme inhibitors. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

 

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries. The data were carefully collected from various industry sources. BCC spoke with officials within the industry and consulted newsletters; company and product literature; and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, the data were compiled from current financial, trade and government sources.

 

ANALYST CREDENTIALS

 

The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Dewan was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents for Chromatography; Spectroscopy, An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.

 

The lead consultant for this project is Dr. Kapil A. Setia, who has a doctorate in life sciences. She has a number of research publications in her credit, including her thesis on "Studies on Phenotypic Variation, Clonal Propagation and Phyto-chemistry of Tinospora cordifolia (Willd.)," which was given an award of excellence.

 

 

 

TABLE OF CONTENTS

 

CHAPTER 1

INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE 1

SCOPE OF REPORT 2

METHODOLOGY AND INFORMATION SOURCES 2

ANALYST CREDENTIALS 2

RELATED REPORTS 2

BCC ON-LINE SERVICES 3

DISCLAIMER 3

CHAPTER 2

SUMMARY 5

SUMMARY TABLE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016 ($

MILLIONS) 6

SUMMARY FIGURE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016 ($

MILLIONS) 6

CHAPTER 3 OVERVIEW 8

DEFINITIONS 8

STRUCTURE OF ENZYMES 8

ACTIVATION ENERGY 8

SPECIFICITY 8

ENZYME SUBSTRATE INTERACTION 9

CONDITIONS OF ENZYME ACTION 9

CLASSIFICATION OF ENZYMES 9

OXIDOREDUCTASES 10

TRANSFERASES 10

HYDROLASES 10

NUCLEASES 11

PHOSPHATASES 11

LYASES 11

ISOMERASES 11

LIGASES 11

REAL-LIFE APPLICATIONS OF ENZYMES 11

METABOLIC ENZYMES 12

DIGESTIVE ENZYMES 13

FOOD ENZYMES 14

NEED FOR ENZYMES IN HUMAN BODY 14

PROTEOLYTIC ENZYMES 14

LIPOLYTIC ENZYMES 15

AMYLOLYTIC ENZYMES 15

RENNIN ENZYMES 15

WHAT ARE ENZYME INHIBITORS 15

WHY ENZYME INHIBITION 15

USE OF ENZYME INHIBITORS 16

MECHANISM OF ENZYME INHIBITION 16

TYPES OF ENZYME INHIBITORS 16

MIXED INHIBITION 17

COMPETITIVE INHIBITION 17

CLASSIFICATION OF ENZYME INHIBITORS 17

TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 17

OXIDOREDUCTASE INHIBITORS 18

ALDOSE REDUCTASE INHIBITORS 18

STATINS 19

HISTORY OF DEVELOPMENT OF STATINS 19

TABLE 2 HISTORY OF DEVELOPMENT OF STATINS 19

5-ALPHA-REDUCTASE INHIBITORS 19

AROMATASE INHIBITORS 20

COX-2 INHIBITORS 20

HYDROLASE INHIBITORS 20

NEURAMINIDASE INHIBITORS 20

PROTEASE INHIBITORS 21

TABLE 3 HISTORY OF DISCOVERY OF PROTEASE INHIBITORS 21

PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS 22

PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS 22

ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 22

TABLE 4 DEVELOPMENT OF ACE INHIBITORS 23

PROTON PUMP INHIBITORS 23

TRANSFERASE INHIBITORS 23

PROTEIN KINASE INHIBITORS 23

REVERSE TRANSCRIPTASE INHIBITORS 24

CHAPTER 4 REGULATORY ASPECTS 26

TABLE 5 NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011 26

TABLE 6 NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS 29

TABLE 7 SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011 30

CHAPTER 5

MARKET LEADERS AND THEIR PRODUCTS FOR ENZYME INHIBITORS 34

TABLE 8 LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS 34

TABLE 9 LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS 34

TABLE 10 LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS 35

TABLE 11 LEADING MANUFACTURERS/SUPPLIERS OF STATINS 35

TABLE 12 LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS 36

TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE

INHIBITORS 36

TABLE 14 LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS 37

TABLE 15 LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS 38

TABLE 16 LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS 38

CHAPTER 6

NEW DEVELOPMENTS 41

TABLE 17 CLINICAL TRIALS ENZYME INHIBITORS 41

TABLE 18 CLINICAL TRIALS OF STATINS 42

TABLE 19 CLINICAL TRIALS FOR AROMATASE INHIBITORS 44

TABLE 20 CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE INHIBITORS 45

TABLE 21 CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS 47

TABLE 22 CLINICAL TRIALS FOR PDE5 INHIBITORS 51

TABLE 23 CLINICAL TRIALS FOR PDE4 INHIBITORS 52

TABLE 24 CLINICAL TRIALS FOR PROTEASE INHIBITORS 52

TABLE 25 CLINICAL TRIALS FOR ACE INHIBITORS 54

TABLE 26 CLINICAL TRIALS FOR PROTON PUMP INHIBITORS 54

NEW DRUGS IN CLINICAL TRIALS 55

TABLE 27 NEW ENZYME INHIBITORS IN CLINICAL TRIALS 55

CHAPTER 7

GLOBAL MARKETS 58

MARKET ANALYSIS 58

TABLE 28 GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 59

FIGURE 1 GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 59

PROTON PUMP INHIBITORS 60

MARKET OVERVIEW 60

MARKET REVENUE 61

TABLE 29 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($ MILLIONS) 61

FIGURE 2 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 62

PROTEASE INHIBITORS 62

MARKET OVERVIEW 62

MARKET REVENUE 63

TABLE 30 GLOBAL MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 63

FIGURE 3 GLOBAL MARKET FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 64

REVERSE TRANSCRIPTASE INHIBITORS 64

MARKET OVERVIEW 65

MARKET REVENUE 66

TABLE 31 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016 ($

MILLIONS) 66

FIGURE 4 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($

MILLIONS) 66

KINASE INHIBITORS 67

MARKET OVERVIEW 67

MARKET REVENUE 69

TABLE 32 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 69

FIGURE 5 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 69

STATINS 70

MARKET OVERVIEW 71

MARKET REVENUE 72

TABLE 33 GLOBAL MARKET FOR STATINS, THROUGH 2016 ($ MILLIONS) 72

FIGURE 6 GLOBAL MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 72

AROMATASE INHIBITORS 73

MARKET OVERVIEW 73

MARKET REVENUE 74

TABLE 34 GLOBAL MARKET FOR AROMATASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 74

FIGURE 7 GLOBAL MARKET FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 74

PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS 75

MARKET OVERVIEW 75

MARKET REVENUE 76

TABLE 35 GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 76

FIGURE 8 GLOBAL MARKET FOR PDE5 INHIBITORS, 2009-2016 ($ MILLIONS) 76

NEURAMINIDASE INHIBITORS 77

MARKET OVERVIEW 77

MARKET REVENUE 78

TABLE 36 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($

MILLIONS) 78

FIGURE 9 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($ MILLIONS) 78

ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 79

MARKET OVERVIEW 80

MARKET REVENUE 80

TABLE 37 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 80

FIGURE 10 GLOBAL MARKET FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 81

MARKET SHARES 81

TABLE 38 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 81

FIGURE 11 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 81

TABLE 39 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82

FIGURE 12 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82

TABLE 40 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83

FIGURE 13 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83

TABLE 41 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83

FIGURE 14 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84

TABLE 42 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84

FIGURE 15 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84

TABLE 43 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85

FIGURE 16 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85

TABLE 44 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85

FIGURE 17 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86

TABLE 45 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86

FIGURE 18 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86

TABLE 46 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87

FIGURE 19 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87

MARKET BY APPLICATIONS 87

TABLE 47 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE

SECTORS, THROUGH 2016 ($ MILLIONS) 88

FIGURE 20 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/

DISEASE SECTORS, 2009-2016 ($ MILLIONS) 88

CARDIOVASCULAR (CV) DISEASE 89

TABLE 48 GLOBAL MARKET FOR ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,

THROUGH 2016 ($ MILLIONS) 90

FIGURE 21 GLOBAL MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,

2009-2016 ($ MILLIONS) 90

GASTROINTESTINAL DISORDERS 91

TABLE 49 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,

THROUGH 2016 ($ MILLIONS) 92

FIGURE 22 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,

2009-2016 ($ MILLIONS) 92

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 93

TABLE 50 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($

MILLIONS) 94

FIGURE 23 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($ MILLIONS) 94

HEPATITIS 94

TABLE 51 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($

MILLIONS) 95

FIGURE 24 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($

MILLIONS) 95

CANCER 96

TABLE 52 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH

2016 ($ MILLIONS) 98

FIGURE 25 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016 ($

MILLIONS) 98

ERECTILE DYSFUNCTION (ED) 99

TABLE 53 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,

THROUGH 2016 ($ MILLIONS) 100

FIGURE 26 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,

2009-2016 ($ MILLIONS) 100

OTHERS 100

TABLE 54 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016

($ MILLIONS) 101

FIGURE 27 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016 ($

MILLIONS) 101

GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION 102

TABLE 55 GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION, 2010 (%) 102

FIGURE 28 GLOBAL MARKET SHARE OF TECHNICAL ENZYMES, 2010 (%) 102

CHAPTER 8 EMERGING MARKETS 105

MARKET ANALYSIS 105

TABLE 56 EMERGING MARKETS FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 106

FIGURE 29 EMERGING MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 106

PROTON PUMP INHIBITORS 107

MARKET OVERVIEW 107

MARKET REVENUE 108

TABLE 57 EMERGING MARKETS FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($

MILLIONS) 108

FIGURE 30 EMERGING MARKETS FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 108

PROTEASE INHIBITORS 109

MARKET OVERVIEW 109

MARKET REVENUE 109

TABLE 58 EMERGING MARKETS FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 109

FIGURE 31 EMERGING MARKETS FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 110

REVERSE TRANSCRIPTASE INHIBITORS 110

MARKET OVERVIEW 110

MARKET REVENUE 111

TABLE 59 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH

2016 ($ MILLIONS) 112

FIGURE 32 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($

MILLIONS) 112

KINASE INHIBITORS 112

MARKET OVERVIEW 113

MARKET REVENUE 114

TABLE 60 EMERGING MARKETS FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 114

FIGURE 33 EMERGING MARKETS FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 114

STATINS 114

MARKET OVERVIEW 115

MARKET REVENUE 116

TABLE 61 EMERGING MARKETS FOR STATINS, THROUGH 2016 ($ MILLIONS) 116

FIGURE 34 EMERGING MARKETS FOR STATINS, 2009-2016 ($ MILLIONS) 116

AROMATASE INHIBITORS 116

MARKET OVERVIEW 117

MARKET REVENUE 117

TABLE 62 EMERGING MARKETS FOR AROMATASE INHIBITORS, THROUGH 2016 ($

MILLIONS) 117

FIGURE 35 EMERGING MARKETS FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 117

PDE5 INHIBITORS 118

MARKET OVERVIEW 118

MARKET REVENUE 118

TABLE 63 EMERGING MARKETS FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 119

FIGURE 36 EMERGING MARKETS FOR PDE5 INHIBITORS, 2009-2016 ($ MILLIONS) 119

NEURAMINIDASE INHIBITORS 119

MARKET OVERVIEW 119

MARKET REVENUE 120

TABLE 64 EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($

MILLIONS) 120

FIGURE 37 EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($

MILLIONS) 120

ACE INHIBITORS 121

MARKET OVERVIEW 121

MARKET REVENUE 121

TABLE 65 EMERGING MARKETS FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 121

FIGURE 38 EMERGING MARKETS FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 122

MARKET SHARES OF INDUSTRY LEADERS IN EMERGING MARKETS 122

PROTON PUMP INHIBITORS 122

TABLE 66 EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS,

2010 (%) 122

FIGURE 39 EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS,

2010 (%) 122

PROTEASE INHIBITORS 123

TABLE 67 EMERGING MARKET SHARES OF PROTEASE INHIBITOR MANUFACTURERS, 2010

(%) 123

FIGURE 40 EMERGING MARKETS SHARES OF PROTEASE INHIBITORS MANUFACTURERS,

2010 (%) 123

KINASE INHIBITORS 124

TABLE 68 EMERGING MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010 (%) 124

FIGURE 41 EMERGING MARKET SHARES OF KINASE INHIBITORS MANUFACTURERS, 2010 (%) 124

STATINS 125

TABLE 69 EMERGING MARKET SHARES OF STATINS MANUFACTURERS, 2010 (%) 125

FIGURE 42 EMERGING MARKETS SHARES OF STATINS MANUFACTURERS, 2010 (%) 125

AROMATASE INHIBITORS 126

TABLE 70 EMERGING MARKET SHARES OF AROMATASE INHIBITOR, 2010 (%) 126

FIGURE 43 EMERGING MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS,

2010 (%) 126

REVERSE TRANSCRIPTASE INHIBITORS 127

TABLE 71 EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR

MANUFACTURERS, 2010 (%) 127

FIGURE 44 EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE MANUFACTURERS,

2010 (%) 127

PDE5 INHIBITORS 128

TABLE 72 EMERGING MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010 (%) 128

FIGURE 45 EMERGING MARKET SHARES OF PED5 MANUFACTURERS, 2010 (%) 128

NEURAMINIDASE INHIBITORS 129

TABLE 73 EMERGING MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS,

2010 (%) 129

FIGURE 46 EMERGING MARKET SHARES OF NEURAMINIDASE MANUFACTURERS, 2010 (%) 129

ACE INHIBITORS 130

TABLE 74 EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%) 130

FIGURE 47 EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%) 130

MARKET BY APPLICATIONS 130

TABLE 75 EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC

CATEGORIES/DISEASE SECTORS, THROUGH 2016 ($ MILLIONS) 131

FIGURE 48 EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC

CATEGORIES/DISEASE SECTORS ($ MILLIONS) 131

CARDIOVASCULAR (CV) DISEASE 132

TABLE 76 EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES,

THROUGH 2016 ($ MILLIONS) 134

FIGURE 49 EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES,

2009-2016 ($ MILLIONS) 134

GASTROINTESTINAL DISORDERS 134

TABLE 77 EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASES,

THROUGH 2016 ($ MILLIONS) 135

FIGURE 50 EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL

DISEASES, 2009-2016 ($ MILLIONS) 135

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 135

TABLE 78 EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($

MILLIONS) 136

FIGURE 51 EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($

MILLIONS) 136

HEPATITIS 137

TABLE 79 EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($

MILLIONS) 138

FIGURE 52 EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($

MILLIONS) 138

CANCER 139

TABLE 80 EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH

2016 ($ MILLIONS) 140

FIGURE 53 EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS,

2009-2016 ($ MILLIONS) 140

ERECTILE DYSFUNCTION (ED) 140

TABLE 81 EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,

THROUGH 2016 ($ MILLIONS) 141

FIGURE 54 EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,

2009-2016 ($ MILLIONS) 141

OTHER DISEASES 141

TABLE 82 EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, THROUGH

2016 ($ MILLIONS) 142

FIGURE 55 EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, 2009-2016

($ MILLIONS) 142

CHAPTER 9 PATENT ANALYSIS 144

PATENTS BY YEAR 144

TABLE 83 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008-2012 144

FIGURE 56 NUMBER OF PATENTS BY YEAR, 2008-2012 144

FIGURE 57 NUMBER OF PATENTS BY YEAR, 2008-2012 (%) 145

PATENTS BY TYPE 145

TABLE 84 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008-2012 146

FIGURE 58 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008–2012 146

PATENTS BY COMPANY 147

TABLE 85 NUMBER OF U.S. PATENTS BY COMPANY FOR ENZYME INHIBITORS, 2008-2012 147

PATENTS BY COUNTRY 148

TABLE 86 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,

2008-2012 148

FIGURE 59 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,

2008–2012 149

TABLE 87 PATENT SHARES BY COUNTRY FOR INDUSTRIAL ENZYMES, 2008-2012 (%) 150

FIGURE 60 PATENT SHARES BY COUNTRY FOR ENZYME INHIBITORS, 2008–2012 (%) 150

PATENTS BY ASSIGNEE 150

TABLE 88 PATENTS BY TYPE FOR INDUSTRIAL ENZYMES, 2008-2012 151

FIGURE 61 PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES, 2008–2012 (%) 151

CHAPTER 10 CURRENT SITUATION 153

MARKET CONDITIONS 153

UNITED STATES 153

EUROPE 153

EMERGING MARKETS 153

TRENDS AND ISSUES IN ENZYME INHIBITORS MARKET 154

COMPETITION 154

PATENT EXPIRATIONS 154

UPCOMING PATENT EXPIRATIONS/UPCOMING PATENT CLIFF 154

PATENT CHALLENGES / LEGAL PROCEEDINGS 154

NEW INDICATIONS APPROVED 155

NEW DRUG APPROVALS 155

RX- TO- OTC SWITCH 156

INCREASING NUMBER OF BABY BOOMERS 156

MERGERS AND ACQUISITIONS AND ALLIANCES 156

DIRECT-TO-CONSUMER ADVERTISING 157

CHAPTER 11 COMPANY PROFILES 159

ABBOTT LABORATORIES 159

AMGEN INC. 159

ASTRAZENECA PLC 159

AUROBINDO PHARMA 160

BAYER HEALTHCARE PHARMACEUTICALS 160

BOEHRINGER INGELHEIM GMBH 161

BRISTOL-MYERS SQUIBB 161

CIPLA LTD. 162

DR. REDDY'S LABORATORIES LTD. 162

EISAI INC. 163

ELI LILLY & CO. 163

ENDO PHARMACEUTICALS 164

GILEAD SCIENCES INC. 164

GLAXOSMITHKLINE PLC 164

GLENMARK GENERICS LTD. 165

HETERO DRUGS LTD. 165

HOFFMAN-LA ROCHE LTD. 166

INCYTE CORP. 166

JOHNSON & JOHNSON 167

LUPIN PHARMACEUTICALS INC. 167

MERCK & CO. INC. 168

MERCK SERONO SA 168

MYLAN LABORATORIES INC. 169

MYLAN LABORATORIES LTD. 169

NOVARTIS AG 170

OSI PHARMACEUTICALS LLC 170

PAR PHARMACEUTICAL COMPANIES INC. 171

PFIZER INC. 171

RANBAXY LABORATORIES LTD. 172

ROXANE LABORATORIES LTD. 172

SANDOZ 173

SANOFI-AVENTIS 173

SANTARUS INC. 174

SUN PHARMACEUTICALS 174

TAKEDA PHARMACEUTICAL CO. LTD. 175

TEVA PHARMACEUTICAL INDUSTRIES LTD. 175

VERTEX PHARMACEUTICALS 175

VIIV HEALTHCARE 176

WATSON PHARMACEUTICALS INC. 176

CHAPTER 12 APPENDIX—ABBREVIATIONS 179

 

LIST OF TABLES

TABLE HEADING PAGE NO.

SUMMARY TABLE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016 ($

MILLIONS) 6

TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 17

TABLE 2 HISTORY OF DEVELOPMENT OF STATINS 19

TABLE 3 HISTORY OF DISCOVERY OF PROTEASE INHIBITORS 21

TABLE 4 DEVELOPMENT OF ACE INHIBITORS 23

TABLE 5 NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-2011 26

TABLE 6 NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS 29

TABLE 7 SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011 30

TABLE 8 LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS 34

TABLE 9 LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS 34

TABLE 10 LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS 35

TABLE 11 LEADING MANUFACTURERS/SUPPLIERS OF STATINS 35

TABLE 12 LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS 36

TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE

INHIBITORS 36

TABLE 14 LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS 37

TABLE 15 LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS 38

TABLE 16 LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS 38

TABLE 17 CLINICAL TRIALS ENZYME INHIBITORS 41

TABLE 18 CLINICAL TRIALS OF STATINS 42

TABLE 19 CLINICAL TRIALS FOR AROMATASE INHIBITORS 44

TABLE 20 CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE INHIBITORS 45

TABLE 21 CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS 47

TABLE 22 CLINICAL TRIALS FOR PDE5 INHIBITORS 51

TABLE 23 CLINICAL TRIALS FOR PDE4 INHIBITORS 52

TABLE 24 CLINICAL TRIALS FOR PROTEASE INHIBITORS 52

TABLE 25 CLINICAL TRIALS FOR ACE INHIBITORS 54

TABLE 26 CLINICAL TRIALS FOR PROTON PUMP INHIBITORS 54

TABLE 27 NEW ENZYME INHIBITORS IN CLINICAL TRIALS 55

TABLE 28 GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 59

TABLE 29 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($ MILLIONS) 61

TABLE 30 GLOBAL MARKET FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 63

TABLE 31 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016 ($

MILLIONS) 66

TABLE 32 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 69

TABLE 33 GLOBAL MARKET FOR STATINS, THROUGH 2016 ($ MILLIONS) 72

TABLE 34 GLOBAL MARKET FOR AROMATASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 74

TABLE 35 GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 76

TABLE 36 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 78

TABLE 37 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 80

TABLE 38 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 81

TABLE 39 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82

TABLE 40 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83

TABLE 41 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83

TABLE 42 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84

TABLE 43 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85

TABLE 44 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85

TABLE 45 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86

TABLE 46 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87

TABLE 47 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE

SECTORS, THROUGH 2016 ($ MILLIONS) 88

TABLE 48 GLOBAL MARKET FOR ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,

THROUGH 2016 ($ MILLIONS) 90

TABLE 49 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,

THROUGH 2016 ($ MILLIONS) 92

TABLE 50 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($

MILLIONS) 94

TABLE 51 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($

MILLIONS) 95

TABLE 52 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH 2016

($ MILLIONS) 98

TABLE 53 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,

THROUGH 2016 ($ MILLIONS) 100

TABLE 54 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016 ($

MILLIONS) 101

TABLE 55 GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION, 2010 (%) 102

TABLE 56 EMERGING MARKETS FOR ENZYME INHIBITORS, THROUGH 2016 ($ MILLIONS) 106

TABLE 57 EMERGING MARKETS FOR PROTON PUMP INHIBITORS, THROUGH 2016 ($

MILLIONS) 108

TABLE 58 EMERGING MARKETS FOR PROTEASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 109

TABLE 59 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH

2016 ($ MILLIONS) 112

TABLE 60 EMERGING MARKETS FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 114

TABLE 61 EMERGING MARKETS FOR STATINS, THROUGH 2016 ($ MILLIONS) 116

TABLE 62 EMERGING MARKETS FOR AROMATASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 117

TABLE 63 EMERGING MARKETS FOR PDE5 INHIBITORS, THROUGH 2016 ($ MILLIONS) 119

TABLE 64 EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, THROUGH 2016 ($

MILLIONS) 120

TABLE 65 EMERGING MARKETS FOR ACE INHIBITORS, THROUGH 2016 ($ MILLIONS) 121

TABLE 66 EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS,

2010 (%) 122

TABLE 67 EMERGING MARKET SHARES OF PROTEASE INHIBITOR MANUFACTURERS, 2010

(%) 123

TABLE 68 EMERGING MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010 (%) 124

TABLE 69 EMERGING MARKET SHARES OF STATINS MANUFACTURERS, 2010 (%) 125

TABLE 70 EMERGING MARKET SHARES OF AROMATASE INHIBITOR, 2010 (%) 126

TABLE 71 EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR

MANUFACTURERS, 2010 (%) 127

TABLE 72 EMERGING MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010 (%) 128

TABLE 73 EMERGING MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS,

2010 (%) 129

TABLE 74 EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%) 130

TABLE 75 EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC

CATEGORIES/DISEASE SECTORS, THROUGH 2016 ($ MILLIONS) 131

TABLE 76 EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES,

THROUGH 2016 ($ MILLIONS) 134

TABLE 77 EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASES,

THROUGH 2016 ($ MILLIONS) 135

TABLE 78 EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016 ($

MILLIONS) 136

TABLE 79 EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016 ($

MILLIONS) 138

TABLE 80 EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH

2016 ($ MILLIONS) 140

TABLE 81 EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,

THROUGH 2016 ($ MILLIONS) 141

TABLE 82 EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, THROUGH

2016 ($ MILLIONS) 142

TABLE 83 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008-2012 144

TABLE 84 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008-2012 146

TABLE 85 NUMBER OF U.S. PATENTS BY COMPANY FOR ENZYME INHIBITORS, 2008-2012 147

TABLE 86 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,

2008-2012 148

TABLE 87 PATENT SHARES BY COUNTRY FOR INDUSTRIAL ENZYMES, 2008-2012 (%) 150

TABLE 88 PATENTS BY TYPE FOR INDUSTRIAL ENZYMES, 2008-2012 151

 

LIST OF FIGURES

SUMMARY FIGURE GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016 ($

MILLIONS) 6

FIGURE 1 GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 59

FIGURE 2 GLOBAL MARKET FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 62

FIGURE 3 GLOBAL MARKET FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 64

FIGURE 4 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($

MILLIONS) 66

FIGURE 5 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 69

FIGURE 6 GLOBAL MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 72

FIGURE 7 GLOBAL MARKET FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 74

FIGURE 8 GLOBAL MARKET FOR PDE5 INHIBITORS, 2009-2016 ($ MILLIONS) 76

FIGURE 9 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($ MILLIONS) 78

FIGURE 10 GLOBAL MARKET FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 81

FIGURE 11 PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010 (%) 81

FIGURE 12 PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 82

FIGURE 13 REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 83

FIGURE 14 KINASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84

FIGURE 15 STATINS INHIBITOR MARKET SHARES BY REGION, 2010 (%) 84

FIGURE 16 AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 85

FIGURE 17 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86

FIGURE 18 NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 86

FIGURE 19 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 87

FIGURE 20 GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE

SECTORS, 2009-2016 ($ MILLIONS) 88

FIGURE 21 GLOBAL MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE,

2009-2016 ($ MILLIONS) 90

FIGURE 22 GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE,

2009-2016 ($ MILLIONS) 92

FIGURE 23 GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($ MILLIONS) 94

FIGURE 24 GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($ MILLIONS) 95

FIGURE 25 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016 ($

MILLIONS) 98

FIGURE 26 GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,

2009-2016 ($ MILLIONS) 100

FIGURE 27 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016 ($

MILLIONS) 101

FIGURE 28 GLOBAL MARKET SHARE OF TECHNICAL ENZYMES, 2010 (%) 102

FIGURE 29 EMERGING MARKET FOR ENZYME INHIBITORS, 2009-2016 ($ MILLIONS) 106

FIGURE 30 EMERGING MARKETS FOR PROTON PUMP INHIBITORS, 2009-2016 ($ MILLIONS) 108

FIGURE 31 EMERGING MARKETS FOR PROTEASE INHIBITORS, 2009-2016 ($ MILLIONS) 110

FIGURE 32 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016 ($

MILLIONS) 112

FIGURE 33 EMERGING MARKETS FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 114

FIGURE 34 EMERGING MARKETS FOR STATINS, 2009-2016 ($ MILLIONS) 116

FIGURE 35 EMERGING MARKETS FOR AROMATASE INHIBITORS, 2009-2016 ($ MILLIONS) 117

FIGURE 36 EMERGING MARKETS FOR PDE5 INHIBITORS, 2009-2016 ($ MILLIONS) 119

FIGURE 37 EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, 2009-2016 ($ MILLIONS) 120

FIGURE 38 EMERGING MARKETS FOR ACE INHIBITORS, 2009-2016 ($ MILLIONS) 122

FIGURE 39 EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS,

2010 (%) 122

FIGURE 40 EMERGING MARKETS SHARES OF PROTEASE INHIBITORS MANUFACTURERS,

2010 (%) 123

FIGURE 41 EMERGING MARKET SHARES OF KINASE INHIBITORS MANUFACTURERS, 2010 (%) 124

FIGURE 42 EMERGING MARKETS SHARES OF STATINS MANUFACTURERS, 2010 (%) 125

FIGURE 43 EMERGING MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS,

2010 (%) 126

FIGURE 44 EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE MANUFACTURERS,

2010 (%) 127

FIGURE 45 EMERGING MARKET SHARES OF PED5 MANUFACTURERS, 2010 (%) 128

FIGURE 46 EMERGING MARKET SHARES OF NEURAMINIDASE MANUFACTURERS, 2010 (%) 129

FIGURE 47 EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010 (%) 130

FIGURE 48 EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC

CATEGORIES/DISEASE SECTORS ($ MILLIONS) 131

FIGURE 49 EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES,

2009-2016 ($ MILLIONS) 134

FIGURE 50 EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASES,

2009-2016 ($ MILLIONS) 135

FIGURE 51 EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016 ($

MILLIONS) 136

FIGURE 52 EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016 ($

MILLIONS) 138

FIGURE 53 EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016

($ MILLIONS) 140

FIGURE 54 EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION,

2009-2016 ($ MILLIONS) 141

FIGURE 55 EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, 2009-2016

($ MILLIONS) 142

FIGURE 56 NUMBER OF PATENTS BY YEAR, 2008-2012 144

FIGURE 57 NUMBER OF PATENTS BY YEAR, 2008-2012 (%) 145

FIGURE 58 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008–2012 146

FIGURE 59 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS,

2008–2012 149

FIGURE 60 PATENT SHARES BY COUNTRY FOR ENZYME INHIBITORS, 2008–2012 (%) 150

FIGURE 61 PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES, 2008–2012 (%) 151

 

 

 

To order this report:

Drug and Medication Industry: Global Markets for Enzyme Inhibitors -- Focus on Emerging Markets

 

 

More Market Research Report

 

 

 

Check our Industry Analysis and Insights

 

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Breast Cancer Diagnostic and Drug Technologies: Global Markets
2. Watson to Present at the Morgan Stanley 2012 Global Healthcare Conference
3. Accuray Incorporateds CEO to Speak at Morgan Stanley Global Healthcare Conference
4. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
5. Global Medical Fiber Optics Industry
6. Zimmer Holdings to Present at Morgan Stanley 2012 Global Healthcare Conference
7. MarketsandMarkets: The Global Ophthalmology Drugs and Devices Market is Expected to Reach $52.4 Billion by 2017
8. Chromatography Market - Global Scenario, Trends, Industry Analysis, Size, Share And Forecasts, 2012 - 2017
9. Wound Dressing Market - Global Scenario, Trends, Industry Analysis, Size, Share And Forecast, 2011 - 2017
10. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
11. Personalized Medicine - A Global Market Overview
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology:
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
Breaking Medicine News(10 mins):